Medtech Company FEMSelect Raises a $9M Series B for Its Minimally Invasive Approach to Pelvic Floor Ligament Fixation

Medtech Company FEMSelect Raises a $9M Series B for Its Minimally Invasive Approach to Pelvic Floor Ligament Fixation

EnPlace, a meshless, minimally invasive method for fixing the pelvic floor ligaments, was created by FEMSelect. New Age Ventures and TriVentures co-led the $9 million Series B fundraising round. Robin Hood Ventures, Mid Atlantic Bio Angels (MABA), MEDA Angels, Keiretsu Forum Mid-Atlantic, RAD BioMed, Keiretsu Capital, and Transpacific Venture Partners are additional investors in the round. According to the firm, the EnPlace system from FEMSelect is approved by the FDA for pelvic floor ligament fixation for the management of symptomatic uterine prolapse, a problem that affects approximately 50% of women over the age of 50. The uterus is frequently removed during today's operations, which many women would rather not have done. In less than 30 minutes, the technology allows for a minimally intrusive procedure.




Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on May 20, 2024 at 1:14pm